| pembrolizumab alone |
| pembrolizumab (10mg/kg) 2 weeks |
| mML - (neo)adjuvant (NA) | |
| mML - NA - all population 9 | |
| mML - NA - PDL1 positive 1 | |
| mML - 1st line (L1) | |
| mML - L1 - all population 7 | |
| mML - L1 - BRAF mutant 2 | |
| mML - L1 - BRAF wild 3 | |
| mML - 2nd line (L2) | |
| mML - L2 - all population 11 | |
| mML - L2 - BRAF mutant 1 | |
Comparator:
vs ipilimumab alone;
Risk of bias:
low;
some concerns;
high;
NA;